PharmaLundensis AB Logo

PharmaLundensis AB

Develops treatments for heavy metal toxicity and serious respiratory illnesses.

PHAL | SPGR

Overview

Corporate Details

ISIN(s):
SE0003359710 (+5 more)
LEI:
54930082I88D5N3GQ506
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PharmaLundensis AB is a pharmaceutical research company that develops treatments for diseases with significant unmet needs. The company's primary project is PHAL-501, a drug designed to bind and excrete heavy metals like mercury, lead, and cadmium from the body. PHAL-501 is intended to act within the intestine, capturing toxins before they are absorbed into the bloodstream, thus offering a potentially safe and effective treatment for heavy metal toxicity. In addition to this focus, the company is also involved in developing therapies for serious respiratory illnesses, such as chronic obstructive pulmonary disease (COPD).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PharmaLundensis AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PharmaLundensis AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PharmaLundensis AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Tord Staffan Håkan Skogvall Other Buy 2,337 1,986.45 SEK
2025-01-17 SkåneÖrnen AB Other Buy 121,700 96,143.00 SEK
2025-01-17 Tord Staffan Håkan Skogvall Other Buy 10,958 7,999.34 SEK
2024-10-14 SkåneÖrnen AB Other Buy 49,370 19,748.00 SEK
2024-10-09 Tord Staffan Håkan Skogvall Other Buy 27,936 10,336.32 SEK
2024-09-26 SkåneÖrnen AB Other Buy 63,000 29,610.00 SEK
2024-09-20 Bo Wennergren Other Buy 60,000 27,600.00 SEK

Peer Companies

Company Country Ticker View
Chordia Therapeutics,Inc Logo
Developing first-in-class, small-molecule anti-cancer drugs targeting RNA deregulation.
Japan 190A
CHOSA Oncology AB Logo
Develops diagnostics and targeted therapies to personalize platinum-based cancer treatments.
Sweden CHOSA
CINC Corp. Logo
Offers AI marketing analytics and SEO tools leveraging a vast Japanese keyword dataset.
Japan 4378
CIRCULATION Co.,Ltd. Logo
Connects corporations with experts for project-based consulting to solve business challenges.
Japan 7379
CIZZLE BIOTECHNOLOGY HOLDINGS PLC Logo
Developing a CIZ1B biomarker blood test for the early detection of lung cancer.
United Kingdom CIZ
COPRO-HOLDINGS. Co., Ltd. Logo
Dispatches technical personnel to Japan's construction & plant industries.
Japan 7059
A creator agency connecting professionals in creative, tech, medical, and legal sectors.
Japan 4763
Offers IT solutions to financial institutions and develops vaccines for HIV and coronaviruses.
South Korea 040350
CRG HOLDINGS CO.,LTD. Logo
Provides IT-driven HR services, outsourcing, system solutions, and financial advisory.
Japan 7041
CRONEX.CO.,LTD Logo
CRO supplying mini-pigs and bio-tissues for non-clinical R&D in medical and cosmetic industries.
South Korea 215570

Talk to a Data Expert

Have a question? We'll get back to you promptly.